JCM
RLAY icon

Jacobi Capital Management’s Relay Therapeutics RLAY Stock Holding History

Jacobi Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-94
Closed -$3K – 1119
2021
Q3 		$3K Hold
94
– – ﹤0.01% 1285
2021
Q2 		$3K Sell
94
-740
-89% -$24.4K ﹤0.01% 1238
2021
Q1 		$29K Buy
834
+765
+1,109% +$33.2K ﹤0.01% 708
2020
Q4 		$3K Buy
+69
New +$3.12K ﹤0.01% 1120

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobi Capital Management's RLAY Position: Q4 2021 in Review

Jacobi Capital Management sold out of Relay Therapeutics (RLAY) in Q4 2021, closing a stake of 94 shares — an estimated $3K sold.

Jacobi Capital Management first reported a position in RLAY in Q4 2020 and held it in 4 quarters. The position peaked at $29K in Q1 2021. 131 funds tracked by Wall St. Rank hold RLAY as of Q4 2021.

  • Jacobi Capital Management reported no remaining Relay Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 94 Relay Therapeutics shares in Q4 2021, an estimated $3K.
  • Jacobi Capital Management first reported a position in Relay Therapeutics in Q4 2020 and held it in 4 quarters.
  • Jacobi Capital Management's Relay Therapeutics position peaked at $29K in Q1 2021.
  • 131 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.